All rights reserved. No reuse allowed without permission.

1 3 4 **COVID-19 Impact on Patients with Immune-Mediated** 5 Rheumatic Disease: A Comparative Study of Disease Activity 6 and Psychological Well-Being Over Six Months 7 Claudia Marques^{1*¶}, Marcelo M Pinheiro^{2¶}, Jennifer Lopes^{3&}, Sandra Lúcia Euzébio 8 Ribeiro^{4&}, Mary Vânia Marinho de Castro^{4&}, Lilian David de Azevedo Valadares^{5&}, 9 Aline Ranzolin^{5&}, Nicole Pamplona Bueno de Andrade^{6&}, Rafaela Cavalheiro do 10 Espírito Santo^{6&}., Nafice Costa Araújo^{7&}, Cintya Martins Vieira^{8&}, Valéria Valim^{9&}, 11 Flavia Patricia Sena Teixeira Santos^{10&}, Laurindo Ferreira da Rocha Junior^{11&}, 12 Adriana Maria Kakehasi^{10¶}, Ana Paula Monteiro Gomides Reis^{12¶}, Edgard Torres 13 dos Reis-Neto²¶, Gecilmara Salviato Pileggi²¶, Gilda Aparecida Ferreira¹⁰¶, Licia 14 Maria Henrique da Mota^{13¶}, Ricardo Machado Xavier^{6¶}. 15 16 17 Department of Rheumatology, Hospital das Clínicas da Universidade Federal de Pernambuco/Ebserh, 18 Recife, Pernambuco, Brazil 19 2. Department of Rheumatology, Escola Paulista de Medicina/ Universidade Federal de São Paulo 20 (EPM/ UNIFESP), São Paulo, Brazil 21 Postgraduate Program of Translacional Health – Universidade Federal de Pernambuco. 22 Department of Rheumatology, Faculdade de Medicina da Universidade Federal do Amazonas, 23 Manaus, Amazonas, Brazil 24 5. Department of Internal Medicine, Hospital Getúlio Vargas, Recife, Pernambuco, Brazil 25 Department of Rheumatology, Hospital de Clínicas de Porto Alegre / Universidade Federal do Rio 26 Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil 27 Department of Rheumatology, Hospital do Servidor Público Estadual de São Paulo - Instituto de 28 Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil 29 Department of Rheumatology, Hospital Universitário da Universidade Federal de Juiz de Fora, Juiz de 30 Fora, Minas Gerais, Brazil 31 Department of Rheumatology, Universidade Federal de Sergipe 32 10. Department of Rheumatology, Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo 33 Horizonte, Minas Gerais, Brazil 34 11. Department of Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira, Recife, 35 Pernambuco, Brazil 36 12. Department of Rheumatology, Centro Universitário de Brasília 37 13. Department of Rheumatology, Universidade de Brasília 38 39 33 * Corresponding author: 40 41 E-mail: claudia.reumatologia@gmail.com (CM) 42 34 43 3 44 45 37 ¶These authors contributed equally to this work. 46 47 48 38 Et a. These authors also contributed equally to this work 49 SNOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Objectives: To compare the impact of COVID-19 on clinical status and psychological condition in patients with immune-mediated rheumatic diseases (IMRD) infected by SARS-CoV-2 with IMRD controls not infected, during a 6-month follow-up. Methods: The ReumaCoV Brasil is a longitudinal study designed to follow-up IMRD patients for 6 months after COVID-19 (cases) compared with IMRD patients no COVID-19 (controls). Clinical data, disease activity measurements and current treatment regarding IMRD, and COVID-19 outcomes were evaluated in all patients. Disease activity was assessed through validated tools at inclusion and at 3 and 6 months post-COVID-19. The FACIT-F (Functional Assessment of Chronic Illness Therapy) and DASS 21 (Depression, Anxiety and Stress Scale - 21 Items) questionnaires were also applied at 6 months after COVID-19 in both groups before large-scale vaccination. The significance level was set as p<0.05, with a 95% confidence interval. **Results:** A total of 601 patients were evaluated, being 321 cases (IMRD COVID-19+) and 280 controls (IMRD COVID-19 -), predominantly female with similar median age. No significant differences were noted in demographic data between the groups, including comorbidities, disease duration, and IMRD. Disease activity assessment over a 6-month follow-up showed no significant difference between cases and controls. While mean activity scores did not differ significantly, some patients reported worsened disease activity post-COVID-19, particularly in rheumatoid arthritis (RA) (32.2%) and systemic lupus erythematosus (SLE) (23.3%). Post-COVID-19 worsening in RA patients correlated with medical global assessment (MGA) and CDAI scores, with a moderate to large effect size. Diabetes mellitus showed a positive association (OR=7.15), while TNF inhibitors showed a protective effect (OR=0.51). Comparing SLEDAI pre- and postperpetuity.
All rights reserved. No reuse allowed without permission.

COVID-19, a minority showed increased scores, with few requiring treatment changes.

Fatigue, depression, anxiety, and stress were significantly higher in cases compared to

controls. Worsening disease activity post-COVID correlated with worsened FACIT-F

and DASS-21 stress scale in RA patients. No significant associations were found

between COVID-19 outcomes and post-COVID-19 disease activity or psychological

assessments.

Conclusions: Post-COVID-19 IMRD patients show significant psychological well-being deterioration despite similar disease activity scores. The variability in reports on IMRD flares and the potential trigger of SARS-CoV-2 for autoimmune manifestations underline the need for detailed clinical assessment and a comprehensive approach to managing them.

Introduction

The COVID-19 pandemic caused by the SARS-CoV-2 virus represents one of the greatest public health challenges worldwide. The infection has raised concerns about how the disease behaves in patients with immune-mediated rheumatic diseases (IMRD), particularly in terms of flares after infection and immunosuppressive treatment as potential risk factors for COVID-19 severity. Since 2020, much information has been published about the understanding of this association and its implications, but few studies have evaluated rheumatic disease flare prospectively post-COVID-19 (1) and existing data are still controversial.

Some individuals with immune-mediated rheumatic diseases (IMRD) may experience exacerbation following SARS-CoV-2 infection. However, uncertainties persist regarding whether these exacerbations are directly linked to disease activity or represent manifestations associated with COVID-19 itself. The phenomenon

commonly referred to as "Long COVID" has been associated with a diverse range of clinical manifestations, encompassing joint pain, fatigue, and psychological symptoms like depression and anxiety, which can endure for several months post-infection [2]. In patients with IMRD, the presence of these symptoms may be connected to disease flares, introducing ambiguity in determining the appropriate course of treatment. Additionally, some authors have highlighted psychosomatic aspects or a fibromyalgia-like presentation, particularly as the prevalence increased following the initial wave of the pandemic. This increase appears to be more correlated with heightened fears, uncertainties, and lockdown strategies, as biological abnormalities such as impaired immune response or viral persistence have not been conclusively identified yet (2).

This study aimed to assess the disease activity status in patients with immune-mediated rheumatic diseases (IMRD) who had experienced COVID-19, comparing them to those who did not contract the virus, over a 6-month follow-up period. Furthermore, the objective was to delineate the prevalence of fatigue and psychological disorders, including depressive symptoms, anxiety, and stress, and to investigate the potential association of these symptoms with IMRD flares.

Materials and Methods

Study design - ReumaCoV Brasil Cohort

This paper presents the protocol for the ReumaCoV-Brasil Registry protocol as described elsewhere (3). Briefly, a prospective observational cohort was carried out in 13 university centers distributed along all five Brazilian geographic regions, including patients with IMRD and COVID-19 and a comparison group (patients with only IMRD), with a follow-up time of 6 months. Patients were evaluated in three consecutive visits: visit 1 (inclusion), visit 2 (3 months) and visit 3 (6 months), from May to

7 iii ngnio 10001 vod. 110 10000 allowed Williout permission.

December 2020. Disease activity status in the medical record of the most recent consultation, carried out at least in the last 6 months before inclusion, was considered as pre-COVID status. The post-COVID status was that which the patient presented at inclusion in the study.

Disease activity evaluation

In all visits, data related to disease activity was collected, using specific validated instrument, mentioned here are those included in this analysis: Clinical Disease Activity Index (CDAI)(4) for RA patients, Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) (5)in SLE patients, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)(6) for patients with SpA. Besides the activity scores, medical global assessment (MGA) and patient global assessment (PGA) were collected regarding disease activity, using a visual analogue scale (VAS) from 0 to 10 points, being 10 the better score, and the patient opinion regarding DRIM worst since the last visit, also using a VAS from 0 to 10.

Disease flare definition

- Rheumatoid arthritis: worsening of symptoms compared to the pre-COVID-19 state plus an increase of 4.5 points in the CDAI and/or need to change treatment (7).
 - Systemic Lupus Erythematosus: worsening of symptoms compared to the pre-COVID-19 state plus an increase at least 4 points in the SLEDAI and/or need to change treatment (8).
 - Spondyloarthritis: worsening of symptoms compared to the pre-COVID-19 state plus an increase at least 2 points in BASDAI and/or need to change treatment(9).

Psychological distress evaluation

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

At visit 3, two questionnaires were administered: one to assess fatigue, using The Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-F)(10), and other to assess mental symptoms, using The Depression, Anxiety and Stress Scale (DASS-21)(11). The FACIT-F Scale is a short, 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The score varies from 0 to 52, and the lower the result, the higher the level of fatigue. DASS-21 is used as a quantitative measure of distress along the 3 axes of depression (D), anxiety (A) and stress (S) reactions and management. Each of the questions is rated from 0 to 3. Therefore, each of the axes presents partial scores of 0 to 18-24 depending on the number of questions assigned. The study was registered at Brazilian Registry of Clinical Trials RBR-33YTQC and approved by the Brazilian National Research Council (CONEP) under number 3.955.206. All participants were requested to provide explicit opt-in consent prior to participating in the survey.

Statical analysis

The Kolmogorov Smirnoff test was performed to verify the normal distribution of continuous variables. As non-normality was verified, the median was used as a measure of central tendency with the respective interquartile range (IQR).

To verify the association among categorical or continuous variables, the chisquare or Fisher test and Pearson test were used, respectively. The Mann-Whitney test

was used to compare means and to estimate the effect size by calculating the r index and the R squared (R²). The r index was used to evaluate the correlation between two variables: small effect size: 0.10; medium effect size: 0.30 and large effect size: 0.50.

To determine the effect size (ES) for comparing means, Cohen's d test was used, interpreted as follows: 0.2 to 0.3 for small effect (the difference between the groups is subtle); around 0.5 as medium effect (moderate difference between the groups) and 0.8 or more as large effect (substantial difference between the groups). To compare the variables across three visits, the One-way Anova test (CI 95%) was used for repeated measures.

For this analysis, the SPSS statistical package, version 29.0.2.0 and the Graph Pad Prism software, Version 10.1.1 (270), November 21, 2023, were used. The significance level was set at p < 0.05, with 95% confidence interval.

Results

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

A total of 601 patients were evaluated, including 321 cases (IMRD COVID+) and 280 controls (IMRD COVID-), with the majority being female with similar median age. No differences were observed regarding demographic data between the two groups, including comorbidities, disease duration and IMRD. A higher frequency of social isolation was observed in the control group (p=0.001), as well as they were on TNFi treatment (p=0.003). Table 1 summarizes the clinical and demographic data at baseline.

Table 1. Clinical and demographic data of the sample, comparing IMRD patients with COVID-

19 versus without COVID-19 at baseline. Chi square test, unless otherwise noted.

	Cases (IMRD COVID +) n=321		Controls (IMRD COVID N=280	-)	
	n	%	n	%	P-value
Female	275	85.7	237	84.6	0.724
Age (median, IQR)	46 (37-57)	•	49 (38-57)	•	0.136**
Ethnicity					
White		32.7	99	35.3	0.601
Non-white	216	67.3	181	64.7	
Instruction					
Illiterate	1	0.3	2	0.7	0.631
< 8 years	78	24.3	74	26.5	_
> 8 years	242	75.4	204	72.8	
Profession	41	12.0	22	11.7	0.020
Public attendance Health	41	12.8	33	11.7 4.7	0.030
	8	10.6	3		
Security Education	32	10.0	25	9.0	-
	90		77		+
Housewife Others	116	28.1 36.0	129	27.6 45.9	1
Active at work	166	51.9	125	44.8	0.084
Social isolation	162	50.5	188	67.1	0.001
Comorbidities	102	30.3	100	07.1	0.001
Hypertension	123	38.3	120	42.9	0.258
Obesity	48	15.0	34	12.1	0.317
Diabetes	31	9.7	22	7.9	0.438
Lung disease		6.2	16	5.7	0.790
Kidney disease	20	6.2	16	5.7	0.790
Cardiopathy	12	4.3	13	4.6	0.734
No comorbidities	107	33.3	99	35.4	0.602
Smoking	11	3.7	15	4.6	0.580
Ethilism	10	3.1	8	2.8	0.835
Diagnosis					
SLE	137	42.5	112	39.4	0.183
RA	93	28.9	105	37.0	
Axial SpA		7.1	30	10.6	
Psoriatic arthritis		6.5	12	36.4	
Systemic sclerosis		5.3	10	3.6	
Sjögren disease	12	3.7	5	1.8	
Miopathy	7	2.2	2	0.7	
Others	11 (5.15)	3.4	4	1.4	0.14644
Disease duration, years (median, IQR)	10 (5-15)		10 (6-18)		0.146**
Medication IMRD					
Hydroxychloroquine	139	43.3	113	40.4	0.465
Oral corticosteroid		42.7	109	38.9	0.351
Methotrexate		22.4	73	26.1	0.298
TNFi		19.0	82	29.3	0.003
Azathioprine		15.0	30	10.7	0.123
Leflunomide		11.2	23	8.2	0.217
Mycophenolate mofetil		8.7	24	8.6	0.948
Tocilizumab		4.4	23	8.2	0.050 0.762*
Rituximab IL-17i		1.6 2.5	6	0.7	0.762*
JAKi		2.5	4	1.4	0.396*
Abatacept		1.2	2	0.7	0.690*
Abatacept Belimumab		0.9	3	1.1	0.591*
Cyclophosphamide (pulse therapy)		0.9	3	1.1	1.000*
Sulfasalazine	3	0.9	6	2.1	0.316*
Suijasalazine	٦	. **M 1771-:4	0 CL 050/ CL E	4.1	0.310

Chi square test, unless otherwise noted. *Fisher exact test; **Mann-Whitney test; CI 95% SLE: systemic lupus erythematosus; RA:

197

198

195

196

rheumatoid arthritis; Axial SpA: axial spondyloarthritis; Pso arthritis: psoriatic arthritis; TNFi: tumour necrosis factor inhibitor; IL-17i:

interleucine 17 inhibitor; JAKi: janus kinase inhibitor

perpetuity.
All rights reserved. No reuse allowed without permission.

In the group of patients with COVID-19 (n=321), the most frequent symptoms were headache (60.6%), fever (55.6%), dysgeusia (54.3%), asthenia (53.7%), anosmia (52.5%) and cough (49.1%). Dyspnea was reported in 35.1% of cases. The medications used to treat COVID-19 were analgesics (53.7%), azithromycin (40.7%), oral corticosteroids (20.2%) and hydroxychloroquine (10.2%), but 16.1% did not use any medication.

Regarding COVID-19 outcomes, hospital care was sought by 77 (23.9%)


Regarding COVID-19 outcomes, hospital care was sought by 77 (23.9%) patients and 29 (9.0%) were hospitalized. Of these, 3 patients were admitted to the intensive care unit and used mechanical ventilation. None of the patients died.


Disease activity assessment


There was no significant difference comparing cases and controls in a 6-month follow-up (V1, V2, and V3), regardless of IMRD (Figure 1).

Figure 1. Comparison of disease activity scores across the three study visits (v1, V2 e V3) in patients with systemic lupus erythematosus, measured by SLEDAI (A), rheumatoid arthritis, measured by CDAI (B) and axial spondylarthritis patients, measured by BASDAI, comparing cases and controls matched to sex, age and epidemiological exposition.









V1: Visit 1 (inclusion); V2: Visit 2; V3: Visit 3

CDAI: Clinical Disease Activity Score; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index

One-way Anova test (CI 95%), repeated measures, multiple comparison of the mean of each column with the mean of every other column.

221

222

223


224

225

226

Although no difference was demonstrated in the mean activity scores, some patients self-reported worsening of the disease activity after COVID-19 [30 with RA (32.2%), 32 with SLE (23.3%) and 2 with SpA (8.6%)]. Exploring these groups further, we also did not observe any significant difference in the mean activity score in RA and SLE patients (Figure 2).

Figure 2. Comparison of disease activity scores across the three study visits, only in patients with systemic lupus erythematosus (SLEDAI) (A) and rheumatoid arthritis (CDAI) (B) who self-reported clinical worsening after COVID-19



Visit 1 (inclusion); V2: Visit 2; V3: Visit 3.

CDAI: Clinical Disease Activity Score; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.

One-way Anova test (CI 95%), repeated measures, multiple comparison of the mean of each column with the mean of every other column

In RA patients that self-reported worsening of disease activity after COVID-19, we applied the flare definition, comparing the CDAI pre-COVID with the CDAI post-COVID (inclusion), visit 2 and visit 3, in a paired way. At inclusion, 12 patients (40.0%) had an increased CDAI ≥ 4.5 points compared to pre-COVID status, but only 1 required a change in treatment. At visit 2, compared with visit 1, 5 new patients presented an increased CDAI ≥ 4.5 points and 7 patients improved compared to the

previous visit. At visit 3, 12 patients presented an increased CDAI, and of these, 8 new patients, who had not worsened at visit 2, and only one needed change of treatment.

248

249

250

251

252

253

254

255

256

257

264

265

266

267

Besides, we compared the tender joint count (TJC), swollen joint count (SJC), patient global assessment (PGA) and medical global assessment (MGA) across the three visits, no significant difference was observed. Eight patients in this group (26.6%) self-reported worsening of joint manifestations.

Comparing the disease activity in the group of RA patients who self-reported worsening with those who did not worse, there was an association with post-COVID MGA, assessed at baseline (ES= - 0.56; CI95% -1.01 to -0.11, p=0.007) and with CDAI and all its components at visit 3 (Table 2).

Table 2. Comparison between Pre- and Post-COVID mean scores in patients with RA who reported worsening versus those who did not report it in the visit 3

		Worse in	visit 3			
	No)	Yes			
	Maan	CD	Maan	CD	n volue	Independent sample
GD 11 G G G T T D #	Mean	SD	Mean	SD	p-value	effect size (ES)*
CDAI pre-COVID#	17.5	16.2	19.2	14.1	0.330	-0.110 (-0.59 to 0.37)
TJC pre-COVID	5.9	6.8	6.4	5.5	0.369	-0.079 (-0.53 to 0.38)
SJC pre-COVID	3.6	6.0	3.3	5.6	0.404	0.057 (-0.40 to 0.51)
PGA pre-COVID	4.8	3.0	8.6	16.4	0.055	-0.385 (-0.85 to 0.087)
MGA pre-COVID	3.2	2.7	3.8	2.6	0.210	-0.196 (-0.66 to 0.27)
CDAI post-COVID&	19.0	18.4	26.5	19.3	0.040	-0.397 (-0.83 to 0.04)
TJC post-COVID	6.5	8.4	9.7	8.6	0.044	-0.384 (-0.82 to 0.05)
SJC post-COVID	3.1	4.8	4.8	7.0	0.113	-0.271 (-0.70 to 0.16)
PGA post-COVID	5.5	3.1	6.4	2.9	0.090	-0.304 (-0.74 to 0.140)
MGA post-COVID	3.4	2.9	5.0	2.7	0.007	-0.563 (-1.01 to -0.11)
CDAI V3	11.7	9.6	23.6	15.9	0.001	-0.996 (-1.45 to -0.51)
TJC V3	3.5	3.6	7.5	6.9	< 0.001	-0.801 (-1.25 to -0.34)
SJC V3	1.3	2.2	4.7	6.3	0.001	-0.818 (-1.27 to -0.36)
MGA V3	2.7	2.3	5.0	2.2	0.001	-1.003 (-1.46 to -0.53)
PGA V3	4.2	2.7	6.8	2.3	0.001	-1.005 (-1.45 to -0.53)

CDAI: clinical disease activity score; TJC: tender joint count; SJC: swollen joint count; PGA: patient global evaluation; MGA: medical global evaluation. *Cohen's d test (CI95%): 0.2 to 0.3: Small effect - the difference between the groups is subtle. About 0.5: Medium effect - moderate difference between the groups. 0.8 or more: Large effect - substantial difference between the groups.

The size effect for MGA post COVID (V1) mean difference means was moderate (-0.56; CI95% -1.01 to -0.11) and for CDAI (-0.996; CI95% -1.45 to -0.51),

13 TJC (-0.801; CI 95% -1.25 to -0.34), SJC (-0.818; CI-1.27 to -0.36), MGA (-1.003; CI 268 -1.46 to -0.53) and PGA at V3 (-1.005; CI -1.45 to -0.53) was a large effect, 269 demonstrating substantial difference between the groups. 270 271 Post-COVID worsening in patients with RA was associated with diabetes mellitus (OR=7.15; CI95% 1.7-29.4, p=0.005) and protectively with current use of TNF 272 inhibitors before the SARS-CoV-2 infection (OR=0.51; CI95% 0.2-0.9, p=0.026). 273 274 Among the patients with SLE who self-reported worsening of disease after COVID-19, 10 of them reported the appearance of new clinical manifestations. 275 However, no significant differences were observed regarding gender, age, 276 277 comorbidities, or concomitant medications. Worsening was only associated with anosmia, as a symptom of COVID-19 (OR=2.43; CI95% 1.07-5.52, p=0.03). The self-278 reported clinical manifestations by SLE patients who were worse after COVID-19 279 (n=32) at visit 3 were skin rash (5 patients), arthritis (3 patients), proteinuria (2 patients) 280 and interstitial lung disease (1 patient). 281 282 Comparing the SLEDAI pre- and post-COVID through the flare definition, we 283 observed that 6 patients (18.0%) had an increased SLEDAI \geq 4.0 points, but only 2 required a change in treatment. At visit 2, compared with visit 1, most patients showed 284 285 SLEDAI improvement and only 3 patients had it increased at visit 3. However, 3 new patients had an SLEDAI increasing compared with the visit 2. 286

Among SpA patients, only 2 patients self-reported worsening after COVID-19 and one of them had progressive worsening in all three visits, based on the BASDAI.

287

288

289

290


291

There was no statistically significant association between COVID-19 outcomes (hospital care, hospitalization, and ICU admission) with post-COVID disease activity at visit 3.

Fatigue, depression, anxiety, and stress assessment

After a 6-month follow-up, a statistically significant difference was observed through FACIT and DASS 21 questionnaires in their three domains comparing cases and controls (Figure 3).

Figure 3. Comparison among FACIT (A), DASS-21 D (B), DASS-21 A (C) and DASS-21 S (D) scores median (IQR) in cases and controls at visit 3.



IQR: Interquartil range. FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue; DASS-21 D: Depression Anxiety and Stress Scale dominium depression; DASS-21 A: Depression Anxiety and Stress Scale dominium anxiety; DASS-21 S: Depression Anxiety and Stress Scale dominium stress.. Mann-Whitney test; CI=95%

The median FACIT score was 37 (27-44) in cases and 40 (32-47) in controls (p=0.0003); DASS-21 D median in cases was 3 (0-8) and 2 (0-5) in controls (p=0.0005); DASS-21 A median in cases was 4 (1-9) and 3 (1-6) in controls (p<0.001) and DASS-21 S median in cases was 6 (2-12) and 5 (2-9) in controls (p<0.018) No difference was observed regarding the FACIT-F and the DASS-21 scores when comparing patients with RA, SLE and SpA in each case group (Figure 4).

314

315

316

317

322


323

324

325

326

Figure 4. Distribution and comparison among FACIT (A), DASS21 D (B), DASS 21 A (C) and DASS 21 S (D) median scores after a 6-month follow-up in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and axial spondyloarthritis (axSpA) only in cases group (IMRD COVID-19 +)



FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue; DASS-21 D: Depression Anxiety and Stress Scale dominium depression; DASS-21 A: Depression Anxiety and Stress Scale dominium anxiety; DASS-21 S: Depression Anxiety and Stress Scale dominium stress; PsoA: psoriatic arthritis; RA: rheumatoid arthritis; axSpA: axial spondyloarthritis; SLE: systemic lupus erythematosus. Independent-Samples Kruskal-Wallis Test, CI 95%.

There was no association of FACIT or DASS-21 with comorbidities, IMRD endpoints (type and specific therapy), and outcomes related to COVID, such as symptoms and treatment, in univariate linear models. Considering the FACIT-F and DASS-21 scores, there was not significant correlation between the disease activity in RA and SLE patients from case group (Figure 5).

327

328

329

330

331

332

333

334

335

336

337

338

339


340

341

342

343

Figure 5. Correlation between disease activity in patients with systemic lupus erythematosus, measured by SLEDAI, and rheumatoid arthritis, measured by CDAI, only in case group (IMRD COVID-19 +), with FACIT-F (A and E) and DASS 21-D (B and F), DASS 21-A (C and G) and DASS 21-S (D and H) scores



Specifically analyzing the group of patients with worsening of disease activity after COVID-19, we observed that RA patients also had a worsening of FACIT-F (31.5 vs. 36.4; p=0.047) and DASS-21-S (19.0 vs. 13.0; p=0.031) when compared to those with no worsening activity. Also, the means was considered as moderate for FACIT-F (0.47; from 0.03 to 0.91) and DASS 21-S (-0.44; from -0.88 to -0.007) (Table 3). In SLE patients, no significant difference was observed.

Table 3. Comparison among mean scores for FACIT, DASS 21-D, DASS 21-A and DASS-21 S in patients with RA who reported worsening versus those who did not report it

patients with KA who reported worsening versus those who did not report it						
	Worse	<mark>at</mark> visit 3	(RA pat	ients)		
	No	o Yes				
						Independent sample
	Mean	SD	Mean	SD	p-value	effect size*

FACIT	36.4	9.7	31.5	11.3	0.017	0.47 (0.03 to 0.91)
DASS 21-D	9.5	10.5	12.6	10.9	0.094	-0.29 (-0.73 to 0.144)
DASS 21-A	11.3	10.0	14.4	9.9	0.090	-0.30 (-0.73 to 0.13)
DASS 21-S	13.7	12.4	19.0	9.7	0.023	-0.44 (-0.88 to -0.007)

^{*} Cohen's d (C195%): 0.2 to 0.3: Small effect - the difference between the groups is subtle. About 0.5: Medium effect moderate difference between the groups. 0.8 or more: Large effect - substantial difference between the groups.

There was no statistically significant association between COVID-19 outcomes (hospital care, hospitalization, and ICU admission) with FACIT-F and DASS-21 scores at visit 3.

Discussion

344 345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

Our results demonstrated that the disease activity scores did not differ significantly in IMRD patients during a 6-month follow-up after COVID-19 in comparison to those who did not contract the virus. However, the clinical worsening was related to fatigue, depression, anxiety, and stress.

Nowadays, the data regarding the association between SARS-CoV-2 infection and IMRD flare are controversial, especially because the published studies have heterogeneous samples and different designs. Consequently, the current uncertainty revolves around whether the Patient-Reported Outcomes (PROs) are related to IMRD flare itself after COVID-19 or if it is associated with Long Covid or, alternatively, represent a reactive post-infectious immunological response working a potential trigger (1, 12-15).

In rheumatic diseases, a flare is defined as any exacerbation of disease activity that, if persistent, would typically necessitate the initiation or modification of therapy. It signifies a cluster of symptoms of sufficient duration and intensity to warrant the commencement, alteration, or escalation of therapeutic measures (16). In our study, although there was no

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

discernible difference in mean activity scores among patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and spondyloarthritis (SpA), a subgroup of patients reported a deterioration in immune-mediated rheumatic disease (IMRD). In some of these cases, activity scores increased, aligning with the flare definition employed in this investigation. Given the recognized potential for overestimation of IMRD activity tools in patients with conditions like fibromyalgia (17) and other chronic painful disorders, particularly in RA and axial SpA, it becomes imperative to ascertain the presence of "true" disease activity. This determination holds substantial relevance in decision-making processes related to treatment adjustments. Nevertheless, we observed an association between patients' self-reported worsening after 6 months and the Clinical Disease Activity Index (CDAI) score, along with all its individual components, including swollen joint count (SJC). This association suggests a plausible occurrence of flare in this specific subset of patients.

A cross-sectional study, including 32 patients with RA and SpA, demonstrated no relevant change regarding disease activity after COVID-19 in those who interrupted their treatment (1). Data from the COVAD study, a cohort that evaluated 824 patients with IMRD who had at least one SARS-CoV-2 infection, between March 2021 and June 18, 2022 (12), showed that 36.9% of patients experienced at least one flare of the underlying IMRD following COVID-19 infection over a 127 day period (IOR = 62-308 days) from the date of infection to the date of the survey. Females and patients with comorbidities had higher odds of flaring of their disease. Patients who reported flares had worse physical health scores, pain VAS, fatigue VAS, and lower mental health scores compared to those who did not report flares. However, as stated by the authors, "this was a self-reported disease flares without verification by a physician which could

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

19

be impacted by patients' perceptions of flares and their inability to distinguish from ongoing symptoms of long-COVID syndrome or secondary fibromyalgia".

In a study conducted on 92 children with IMRD who have had COVID-19 (13), 10% had a relapse of IMRD after infection. The relapse was mild in four and moderate in five cases. One patient had a severe relapse of ARD and required hospitalization, without association with COVID-19 clinical presentation.

Similar to other several viral infections, SARS-CoV-2 infection could be potential trigger of reactive and autoimmune diseases by inducing type II and type IV hypersensitivity reactions, leading to autoantibodies production and autoimmune diseases development as long-term complications (18), and in patients with pre-existing IMRD, it may be difficult to identify whether it is a flare of the disease or a postinfection manifestation. A recent study evaluated the effects of COVID-19 on the development and progression of RA using a collagen-induced arthritis (CIA) animal model. The incidence and severity of RA in CIA mice were slightly increased by SARS-CoV-2 spike protein in vivo. In addition, the levels of autoantibodies and thrombotic factors, such as anti-CXC chemokine ligand 4 (CXCL4, also called PF4) antibodies and anti-phospholipid antibodies were significantly increased by SARS-CoV-2 spike protein. Furthermore, tissue destruction and inflammatory cytokine level in joint tissue were markedly increased in CIA mice by SARS-CoV-2 spike protein, suggesting that COVID-19 accelerates the development and progression of RA by increasing inflammation, autoantibody production, and thrombosis(19).

In an Italian study, 122 consecutive post-COVID-19 cases were evaluated, with the onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection as an inclusion criterion. In this group, it was identified that most patients had inflammatory joint disease (52.5%); 19.7% of cases were diagnosed with connective

tissue diseases and 6.6% of cases with vasculitis. It is interesting to note that in this same cohort, patients with inflammatory manifestations post-COVID-19 vaccine were evaluated, and this group had a higher prevalence of patients classified as polymyalgia rheumatica (PMR, 33.1% vs. 21.3%, p=0.032) (14). Another study evaluated the presence of arthritis associated with COVID-19 by ultrasound in 10 patients with (n=4) and without previous rheumatic disease (n=6). In the group without previous disease, 4 of the 6 patients presented arthritis for 4 to 16 weeks after infection, comparable to reactive arthritis. One of them developed late-onset rheumatoid arthritis. In the group with previous disease, synovitis and tenosynovitis with positive power Doppler were observed, suggesting a possible flare of the disease after COVID-19 (20).

A major concern when interpreting the musculoskeletal symptoms in these patients is the possibility of developing post-Covid syndrome, also known as long Covid. More than 20% of subjects surviving acute COVID-19 may suffer from persisting symptoms and develop new ones after one month and about 5% of all infected individuals develop long-term complications after 6 months, possible due to tissue damage, viral reservoirs, autoimmunity, and persistent inflammation (21, 22). The clinical presentation in these cases, such as fatigue and joint pain, may mimic a disease flare, thereby complicating the decision-making regarding treatment's change.

Recent systematic review showed that the prevalence of arthralgia ranges from 2% to 65% within a time frame varying from 4 weeks to 12 months after COVID-19. Inflammatory arthritis has been reported with various clinical phenotypes, including RA-like pattern as other prototypical viral arthritis, as well as polymyalgia-like, or acute monoarthritis and oligoarthritis of large joints resembling reactive arthritis or SpA style (23).

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

21

An Iranian study evaluated the prevalence of musculoskeletal symptoms in 239 patients after the acute phase of COVID-19 and its associated factors, using an online questionnaire. Almost all of them (98.74%) had experienced at least one musculoskeletal symptom after recovering from COVID-19, and the most common symptom was fatigue (91.2%), followed by myalgia, headache, and low back pain. High BMI, hospitalization, and ICU admission were associated with a higher risk of musculoskeletal symptoms (24).

Besides musculoskeletal symptoms, patients could develop psychological distress after COVID-19, such as depression, anxiety, and stress, symptoms that could also be present in IMRD. In our patients, the frequency of these symptoms in IMRD post COVID-19 was significantly higher than in patients who did not have the infection. Some authors suggested that the term of long COVID is unappropriated and should be replaced by fibromyalgia-like post-COVID syndrome (2).

We acknowledge the limitations of our study, such as the fact we have the FACIT and DASS 21 scores only at the last visit and no possibility of comparison with the pre-COVID status. Since the study began in the first months of the pandemic, we did not know yet that these outcomes were important. We decided to include it after the first studies were published demonstrating the association of these symptoms with SARS-CoV-2 infection. However, we know that fatigue, depression, anxiety, and stress are frequent symptoms in patients with IMRD and we have a group that did not have COVID-19 as a comparator, and in the group with COVID-19 these scores were significantly worse. In addition, the greater political and economic instability experienced in our country may have had a direct impact on psychological distress as a bias. On the other hand, we have a representative sample, from various regions of Brazil, with a follow-up period of 6 months, compared with a group of patients with

perpetuity.
All rights reserved. No reuse allowed without permission.

22

465 IMRD matched by sex and age, for the same epidemiological period, one of the main strengths of our study.

Conclusions

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

Our observational data underscore the complex interplay between COVID-19 and immune-mediated rheumatic diseases (IMRD). While disease activity scores may not exhibit significant differences, individuals with post-COVID-19 IMRD may undergo noteworthy deterioration in psychological well-being. The variations in reports regarding IMRD flares and the potential triggering role of SARS-CoV-2 in autoimmune manifestations underscore the need for thorough clinical assessment and a comprehensive approach to their management.

Acknowledgements

All ReumaCoV Brazil researchers

References

- 1. 483 Miledi S, Bouzid S, Fazaa A, Sallemi M, Bousaa H, Ben Abdelghani K, Laatar A.
- 484 COVID-19 in Patients with Systemic Inflammatory Diseases: Impact on Disease Activity.
- Curr Rheumatol Rev. 2023;19(3):330-5. 485
- 486 2. Mariette X. Long COVID: a new word for naming fibromyalgia? Ann Rheum Dis.
- 487 2024;83(1):12-4.

- 3. Marques C, Kakehasi AM, Gomides APM, Paiva EDS, Dos Reis Neto ET, Pileggi 488
- 489 GCS, et al. A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory
- 490 Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective,
- 491 Observational Study. JMIR Res Protoc. 2020;9(12):e24357.
- 492 4. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS.
- 493 Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:
- 494 validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
- 495 5. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity
- 496 index 2000. J Rheumatol. 2002;29(2):288-91.
- 497 6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new
- 498 approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing
- 499 Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
- 500 7. Konzett V, Kerschbaumer A, Smolen JS, Kristianslund EK, Provan SA, Kvien TK,
- 501 Aletaha D. Definition of rheumatoid arthritis flare based on SDAI and CDAI. Ann Rheum
- 502 Dis. 2024;83(2):169-76.
- 503 8. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of
- 504 Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and
- 505 minimal clinically meaningful change based on data from a large cohort of systemic lupus
- 506 erythematosus patients. Rheumatology (Oxford). 2011;50(5):982-8.
- 9. 507 Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compan V, Kroon F, et al.
- 508 Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and
- 509 ASDAS-CRP: an ASAS initiative. Ann Rheum Dis. 2016;75(6):991-6.

- 510 10. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a
- 511 new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol.
- 1997;34(3 Suppl 2):13-9. 512
- 11. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress 513
- 514 Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J
- 515 Clin Psychol. 2005;44(Pt 2):227-39.
- 516 12. Sandhu NK, Ravichandraan N, Nune A, Day J, Sen P, Nikiphorou E, et al. Flares of
- 517 autoimmune rheumatic disease following COVID-19 infection: Observations from the
- 518 COVAD study. Int J Rheum Dis. 2024;27(1):e14961.
- 519 13. Sinkovec Savsek T, Zajc Avramovic M, Avcin T, Korva M, Avsic Zupanc T, Toplak
- 520 N. Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19
- 521 infection and vaccination. Pediatr Rheumatol Online J. 2023;21(1):46.
- 522 14. Ursini F, Ruscitti P, Addimanda O, Foti R, Raimondo V, Murdaca G, et al.
- 523 Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19
- 524 vaccination: a report of 267 cases from the COVID-19 and ASD group. RMD Open.
- 525 2023;9(2).
- 526 15. van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. Post-acute and
- 527 long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract.
- 528 2022;39(1):159-67.
- 16. 529 Bingham CO, 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al.
- 530 Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9
- Special Interest Group). J Rheumatol. 2009;36(10):2335-41. 531

- 532 17. Coskun Benlidayi I. Fibromyalgia interferes with disease activity and biological
- 533 therapy response in inflammatory rheumatic diseases. Rheumatol Int. 2020;40(6):849-58.
- 534 18. Votto M, Castagnoli R, Marseglia GL, Licari A, Brambilla I. COVID-19 and
- 535 autoimmune diseases: is there a connection? Curr Opin Allergy Clin Immunol.
- 536 2023;23(2):185-92.
- 19. 537 Lee AR, Woo JS, Lee SY, Lee YS, Jung J, Lee CR, et al. SARS-CoV-2 spike protein
- promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell 538
- 539 Commun Signal. 2023;21(1):44.
- 540 20. Vogler D, Ruscitti P, Navarini L, Giacomelli R, Iagnocco A, Hoff P, et al. Diagnosis
- 541 of COVID-19 associated arthritis in patients with or without underlying rheumatic and
- 542 musculoskeletal disease supported by musculoskeletal ultrasound: a case series from three
- 543 European centres. Clin Exp Rheumatol. 2023;41(3):656-66.
- 544 21. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z,
- 545 Ashbaugh C, et al. Estimated Global Proportions of Individuals With Persistent Fatigue,
- 546 Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020
- 547 and 2021. JAMA. 2022;328(16):1604-15.
- 22. Cervia-Hasler C, Bruningk SC, Hoch T, Fan B, Muzio G, Thompson RC, et al. 548
- 549 Persistent complement dysregulation with signs of thromboinflammation in active Long
- 550 Covid. Science. 2024;383(6680):eadg7942.
- 23. Ciaffi J, Vanni E, Mancarella L, Brusi V, Lisi L, Pignatti F, et al. Post-Acute 551
- 552 COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic
- 553 Review. Diagnostics (Basel). 2023;13(11).

554 24. Azadvari M, Haghparast A, Nakhostin-Ansari A, Emami Razavi SZ, Hosseini M. Musculoskeletal symptoms in patients with long COVID: A cross-sectional study on Iranian 555 patients. Heliyon. 2022;8(8):e10148. 556 557

558